B of A Securities Maintains Neutral on 10x Genomics, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 53.9%

Neg 0% Neu 0% Pos 53.9%

B of A Securities analyst Derik De Bruin maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $21 to $30.